GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.
The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.
GRI Bio, Inc. director David Leslie Szekeres received a stock option grant on 08/13/2025 to purchase 7,545 shares of common stock. The Form 4 shows the derivative award is a stock option with a stated $1.30 conversion/exercise price and an expiration date of 08/13/2035. The option was reported as acquired on 08/13/2025 and is held directly. The award vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date, per the filing. The Form 4 was signed by an attorney-in-fact on 08/14/2025.
GRI Bio is a clinical-stage biopharmaceutical company advancing oral iNKT/dNKT modulators. The company reported a net loss of $2.89 million for the quarter and $5.94 million for the six months ended June 30, 2025, driven by higher research and development spending on GRI-0621 ($1.88 million in Q2; $3.52 million six months) and ongoing company overhead.
Cash and cash equivalents were $5.12 million at period end; management forecasts this funding will support operations into the fourth quarter of 2025 but discloses substantial doubt about going concern without additional financing. Clinical progress includes completion of Phase 2a enrollment in July 2025, an Independent Data Monitoring Committee review reporting no safety concerns for early cohorts, and topline biomarker results expected in Q3 2025. Recent financings include an April 2025 offering (net $4.02 million) and ATM sales (net $4.29 million through June 30, 2025). The company disclosed a material weakness in internal controls.
GRI Bio, Inc. filed a Form S-8 to register an additional 400,000 shares of common stock reserved for issuance under its Amended and Restated 2018 Equity Incentive Plan. The filing incorporates prior Form S-8 registrations by reference and includes the amended plan and related award agreement forms as exhibits. The registration increases the pool available for employee stock awards but does not disclose total shares outstanding or quantify potential dilution.
GRI Bio, Inc. reported results from its August 13, 2025 virtual Annual Meeting. Stockholders approved an amendment to the Amended and Restated 2018 Equity Incentive Plan, increasing the number of shares reserved for issuance by 400,000 shares. The company noted 2,496,800 shares issued and outstanding as of the July 8, 2025 record date and a quorum of 1,090,373 shares (approximately 43.67%) was present or represented.
At the meeting the board nominees Roelof Rongen and Camilla V. Simpson were elected with 63,031 and 63,581 votes for, respectively, and the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal 2025 was ratified with 1,072,167 votes for. Exhibit 10.1 contains the amended equity incentive plan text.
GRI Bio (Nasdaq: GRI) furnished an 8-K under Item 7.01 disclosing a press release that reports interim safety results from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis. The disclosure is provided solely for Regulation FD purposes and is expressly not deemed “filed” under the Exchange Act. No efficacy data, financial metrics, or guidance updates were included. Exhibit 99.1 contains the full press release; no other material items were reported.